Greenwich LifeSciences, Inc. (GLSI)
$11.98
+0.33 (+2.83%)
Rating:
Recommendation:
-
| Symbol | GLSI |
|---|---|
| Price | $11.98 |
| Beta | 3.195 |
| Volume Avg. | 0.01M |
| Market Cap | 153.921M |
| Shares () | - |
| 52 Week Range | 7.58-21.5 |
| 1y Target Est | - |
| DCF Unlevered | GLSI DCF -> | |
|---|---|---|
| DCF Levered | GLSI LDCF -> | |
| ROE | -78.09% | Strong Sell |
| ROA | -94.74% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -17.11 | Strong Sell |
| P/B | 17.39 | Strong Buy |
Latest GLSI news
About
Download (Excel)Mr. Snehal S. Patel
Healthcare
Biotechnology
NASDAQ Capital Market
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.